Weekly Investment Analysts’ Ratings Updates for Kiniksa Pharmaceuticals International (KNSA)

Several brokerages have updated their recommendations and price targets on shares of Kiniksa Pharmaceuticals International (NASDAQ: KNSA) in the last few weeks:

• 5/6/2026 – Kiniksa Pharmaceuticals International was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 5/4/2026 – Kiniksa Pharmaceuticals International was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 4/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by Canaccord Genuity Group Inc. from $62.00 to $64.00. They now have a “buy” rating on the stock.
• 4/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by Citigroup Inc. from $50.00 to $60.00. They now have a “buy” rating on the stock.
• 4/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wedbush from $58.00 to $59.00. They now have an “outperform” rating on the stock.
• 4/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wells Fargo & Company from $53.00 to $57.00. They now have an “overweight” rating on the stock.
• 4/28/2026 – Kiniksa Pharmaceuticals International had its price target raised by Jefferies Financial Group Inc. from $58.00 to $71.00. They now have a “buy” rating on the stock.
• 4/26/2026 – Kiniksa Pharmaceuticals International was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/21/2026 – Kiniksa Pharmaceuticals International had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 4/18/2026 – Kiniksa Pharmaceuticals International was upgraded by Wall Street Zen from “hold” to “buy”.
• 4/17/2026 – Kiniksa Pharmaceuticals International was downgraded by Zacks Research from “hold” to “strong sell”.
• 4/16/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wedbush from $53.00 to $58.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CEO Sanj K. Patel sold 48,565 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the sale, the chief executive officer directly owned 48,565 shares in the company, valued at $2,623,481.30. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the sale, the director owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. The trade was a 51.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.